arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
November 19, 2021 09:55 ET | Arvinas Inc.
NEW HAVEN, Conn. and NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) announced today that updated safety and efficacy data from the Phase 1 dose...
arvinas_logoART_lg.jpg
Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
November 10, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 03, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix.png
Nurix Therapeutics Announces Initial Data from the First Phase 1a Dose Escalation Trial of NX-2127 in Patients with Relapsed or Refractory B Cell Malignancies
October 27, 2021 07:00 ET | Nurix Therapeutics, Inc.
Robust BTK target degradation achieved in all patients treated to date Greater than 90% degradation of BTK was achieved at the 200 mg dose of NX-2127 These data represent the first proof of...
Nurix.png
Nurix Therapeutics to Present Initial Target Degradation Data from First Phase 1 Trial of NX-2127 in B Cell Malignancies at the 4th Annual Targeted Protein Degradation Summit
October 26, 2021 16:02 ET | Nurix Therapeutics, Inc.
Presentation to include initial pharmacokinetic and BTK degradation data Company to host conference call at 8:30 a.m. ET on Wednesday, October 27, 2021 SAN FRANCISCO, Oct. 26, 2021 (GLOBE...
Nurix.png
Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
October 21, 2021 07:00 ET | Nurix Therapeutics, Inc.
SAN FRANCISCO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Nurix’s...
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Virtual Investor Conferences
September 01, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
arvinas_logoART_lg.jpg
Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 05, 2021 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
Nurix.png
Nurix Therapeutics Reports Second Quarter Fiscal 2021 Financial Results and Provides a Corporate Update
July 13, 2021 16:01 ET | Nurix Therapeutics, Inc.
Initiated Phase 1 trial of lead program NX-2127 in patients with relapsed or refractory B-cell malignancies On track to initiate Phase 1 trials for three additional wholly owned drug candidates in...
22157.jpg
Global Targeted Protein Degradation Market (2021 to 2030) - by Type of Protein Degrader, Therapeutic Areas, Route of Administration, Key Contributing Technologies and Key Geographies
July 13, 2021 05:18 ET | Research and Markets
Dublin, July 13, 2021 (GLOBE NEWSWIRE) -- The "Targeted Protein Degradation Market: Focus on Technology Platforms and Therapeutics: Distribution by Type of Protein degrader, Therapeutic Areas, Route...